+1 (202) 780-3397Mini Review - Journal of Dermatology Research and Skin Care (2025) Volume 9, Issue 4
Evaluating the efficacy and safety of intralesional acyclovir in the management of recalcitrant cutaneous warts: A Retrospective review of 20 cases.
Background: Recalcitrant cutaneous warts, often resistant to conventional therapies, present a persistent challenge in dermatological practice. Acyclovir, an antiviral agent with activity against herpesviruses, has shown potential immunomodulatory effects that may offer therapeutic benefit in wart management.
Objective: To evaluate the efficacy and safety of intralesional acyclovir in the treatment of recalcitrant cutaneous warts through a retrospective review of clinical outcomes in 20 patients.
Methods: A retrospective analysis was conducted on 20 patients with recalcitrant cutaneous warts who received intralesional acyclovir injections over a six-month period. Data on patient demographics, lesion characteristics, treatment regimen, response rates, adverse effects, and recurrence were collected and analyzed. Results: Of the 20 patients, 14 (70%) demonstrated complete resolution of warts, while 4 (20%) showed partial response. Two patients (10%) had no response to treatment. Minimal adverse effects were reported, primarily localized pain and mild inflammation at the injection site. No systemic side effects were observed. At 3-month follow-up, recurrence was noted in 2 cases (10%).
Conclusion: Intralesional acyclovir appears to be a promising, safe, and well-tolerated treatment option for recalcitrant cutaneous warts, particularly in patients unresponsive to conventional therapies. Larger prospective studies are warranted to confirm these findings and elucidate the underlying mechanisms of action.
Author(s):Diem-Phuong D. Dao*, Michelle A. Robinson, Kristin P. Bibee, Jihad M. Alhariri